Observations placeholder

Valdecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a cyclooxygenase-2 selective inhibitor.

Valdecoxib was manufactured and marketed under the brand name Bextra. It was approved by the United States Food and Drug Administration on November 20, 2001, and was available by prescription in tablet form until 2005, when it was removed from the market due to concerns about possible increased risk of heart attack and stroke. The prodrug parecoxib is available in many countries

On Oct, 6, 2015: 20,475 people reported to have side effects when taking Bextra. Among them, 85 people (0.42%) have Hallucination.

Time on Bextra when people have Hallucination  :

< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Hallucination84.62%0.00%7.69%7.69%0.00%0.00%0.00%

On Oct, 1, 2015: 20,475 people reported to have side effects when taking Bextra. Among them, 380 people (1.86%) have Death.

Time on Bextra when people have Death :

< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death14.52%35.48%12.90%27.42%9.68%0.00%0.00%